Dermira to Present at the 18th Annual Needham Healthcare Conference
April 03 2019 - 3:05PM
Business Wire
Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company
dedicated to bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of
patients living with chronic skin conditions, today announced that
company management will participate in a fireside chat at the 18th
Annual Needham Healthcare Conference on Wednesday, April 10, 2019
at 12:50 p.m. ET.
A live audio webcast and archive of the presentation will be
available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to
bringing biotech ingenuity to medical dermatology by delivering
differentiated, new therapies to the millions of patients living
with chronic skin conditions. Dermira is committed to
understanding the needs of both patients and physicians and using
its insight to identify, develop and commercialize leading-edge
medical dermatology products. The company’s approved treatment,
QBREXZA™ (glycopyrronium) cloth, is indicated for pediatric and
adult patients (ages 9 and older) with primary axillary
hyperhidrosis (excessive underarm sweating). Please see the
QBREXZA prescribing information. Dermira is also evaluating
lebrikizumab for the treatment of moderate-to-severe atopic
dermatitis (a severe form of eczema) and plans to initiate a Phase
3 clinical development program by the end of 2019; and has
early-stage research and development programs in other areas of
dermatology. Dermira is headquartered in Menlo Park,
Calif. For more information, please
visit http://www.dermira.com. Follow Dermira
on Twitter, LinkedIn and Instagram.
In addition to filings with the Securities and Exchange
Commission (SEC), press releases, public conference calls and
webcasts, Dermira uses its website (www.dermira.com),
LinkedIn page (https://www.linkedin.com/company/dermira-inc-),
corporate Instagram account
(https://www.instagram.com/dermira_inc/) and corporate Twitter
account (@DermiraInc) as channels of distribution of information
about its company, product candidates, planned financial and other
announcements, attendance at upcoming investor and industry
conferences and other matters. Such information may be deemed
material information and Dermira may use these channels
to comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Dermira’s website, LinkedIn
page, Instagram and Twitter accounts in addition to following
its SEC filings, news releases, public conference calls
and webcasts.
Forward-Looking Statements
The information in this news release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the “safe harbor” created by those sections. This news release
contains forward-looking statements that involve substantial risks
and uncertainties, including statements with respect to Dermira’s
goal of bringing biotech ingenuity to medical dermatology by
delivering differentiated, new therapies to the millions of
patients living with chronic skin conditions and Dermira’s plans to
initiate a Phase 3 development program for lebrikizumab by the end
of 2019. These statements deal with future events and involve known
and unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from the information expressed or implied by these
forward-looking statements. Factors that could cause actual results
to differ materially include risks and uncertainties such as those
relating to Dermira’s dependence on third-party clinical research
organizations, manufacturers, suppliers and distributors; the
design and implementation of Dermira’s clinical trials; the
outcomes of future meetings with regulatory agencies; Dermira’s
ability to attract and retain key employees; Dermira’s ability to
manage the growth and complexity of its organization; Dermira’s
ability to maintain, protect and enhance its intellectual property;
and Dermira’s ability to continue to stay in compliance with its
material contractual obligations, applicable laws and regulations.
You should refer to the section entitled “Risk Factors” set forth
in Dermira’s Annual Report on Form 10-K, Dermira’s Quarterly
Reports on Form 10-Q and other filings Dermira makes with
the SEC from time to time for a discussion of important
factors that may cause actual results to differ materially from
those expressed or implied by Dermira’s forward-looking statements.
Furthermore, such forward-looking statements speak only as of the
date of this news release. Dermira undertakes no
obligation to publicly update any forward-looking statements or
reasons why actual results might differ, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190403005717/en/
Media:Erica JeffersonVice President, Corporate
Communications650-421-7216media@dermira.com
Investors:Andrew GuggenhimeChief Financial
Officer650-421-7200investor@dermira.com
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Jul 2023 to Jul 2024